{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T05:24:50Z","timestamp":1774502690353,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T00:00:00Z","timestamp":1555027200000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.heliyon.2019.e01518","type":"journal-article","created":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T16:00:29Z","timestamp":1555689629000},"page":"e01518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Development and validation of eco-friendly micellar-HPLC and HPTLC-densitometry methods for the simultaneous determination of paritaprevir, ritonavir and ombitasvir in pharmaceutical dosage forms"],"prefix":"10.1016","volume":"5","author":[{"given":"Adel Ehab","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roshdy E.","family":"Saraya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanaa","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magda","family":"Elhenawee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2019.e01518_bib1","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2471\/BLT.15.157784","article-title":"Access to hepatitis C medicines","volume":"93","author":"Edwards","year":"2015","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.heliyon.2019.e01518_bib2","doi-asserted-by":"crossref","first-page":"17311","DOI":"10.1038\/s41598-017-17701-7","article-title":"Development of decision forest models for prediction of drug-induced liver injury in humans using a large set of FDA-approved drugs","volume":"7","author":"Hong","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2019.e01518_bib3","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/infdis\/jix495","article-title":"Hepatic pharmacokinetics and pharmacodynamics with ombitasvir\/paritaprevir\/ritonavir plus dasabuvir treatment and variable ribavirin dosage","volume":"217","author":"Talal","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2019.e01518_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1478-3231.2010.02385.x","article-title":"Hepatitis C virus genotype 4 therapy: progress and challenges","volume":"31","author":"Kamal","year":"2011","journal-title":"Liver Int."},{"key":"10.1016\/j.heliyon.2019.e01518_bib5","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1002\/jssc.201800567","article-title":"Development of a highly sensitive high-performance thin-layer chromatography method for the screening and simultaneous determination of sofosbuvir, daclatasvir, and ledipasvir in their pure forms and their different pharmaceutical formulations","volume":"41","author":"Saraya","year":"2018","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.heliyon.2019.e01518_bib6","doi-asserted-by":"crossref","DOI":"10.14233\/ajchem.2018.21215","article-title":"Stability-indicating RP-HPLC method for simultaneous quantification of ombitasvir, paritaprevir and ritonavir in tablet dosage form","volume":"30","author":"Kuna","year":"2018","journal-title":"Asian J. Chem."},{"key":"10.1016\/j.heliyon.2019.e01518_bib7","first-page":"28","article-title":"Development and validation of a new, simple-HPLC method for simultaneous determination of ombitasvir, paritaprevir, ritonavir and ribavirin in tablet dosage form","volume":"12","author":"Wadie","year":"2017","journal-title":"IOSR J. Pharm. Biol. Sci."},{"key":"10.1016\/j.heliyon.2019.e01518_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13065-016-0232-6","article-title":"Simultaneous determination of newly developed antiviral agents in pharmaceutical formulations by HPLC-DAD","volume":"11","author":"Al-Zoman","year":"2017","journal-title":"Chem. Cent. J."},{"key":"10.1016\/j.heliyon.2019.e01518_bib9","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.13005\/ojc\/330528","article-title":"New analytical HPLC method development and validation for the simultaneous quantification of paritaprevir ombitasvir and ritonavir in spiked human plasma","volume":"33","author":"Ch","year":"2017","journal-title":"Orient. J. Chem."},{"key":"10.1016\/j.heliyon.2019.e01518_bib10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jpba.2016.04.031","article-title":"A UHPLC\u2013MS\/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir\/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma","volume":"125","author":"Ariaudo","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.heliyon.2019.e01518_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jchromb.2017.03.020","article-title":"Ultra-performance liquid chromatography tandem mass spectrometry for determination of Direct Acting Antiviral drugs in human liver fine needle aspirates","volume":"1052","author":"Ocque","year":"2017","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.heliyon.2019.e01518_bib12","series-title":"Validation of Analytical Procedures: Text and Methodology Q2 (R1)","first-page":"11","author":"ICH, Guidelines","year":"2005"},{"key":"10.1016\/j.heliyon.2019.e01518_bib13","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1002\/jssc.201701263","article-title":"Comparison between core\u2013shell and totally porous particle stationary phases for fast and green LC determination of five hepatitis-C antiviral drugs","volume":"41","author":"Ibrahim","year":"2018","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.heliyon.2019.e01518_bib14","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1039\/b906215g","article-title":"Performance to burn? Re-evaluating the choice of acetonitrile as the platform solvent for analytical HPLC","volume":"11","author":"Welch","year":"2009","journal-title":"Green Chem."},{"key":"10.1016\/j.heliyon.2019.e01518_bib15","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.5740\/jaoacint.18-0001","article-title":"Performance comparison between monolithic, core-shell, and totally porous particulate columns for application in greener and faster chromatography","volume":"101","author":"Ibrahim","year":"2018","journal-title":"J. AOAC Int."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844019310667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844019310667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:39:00Z","timestamp":1762511940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844019310667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S2405844019310667"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2019.e01518","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of eco-friendly micellar-HPLC and HPTLC-densitometry methods for the simultaneous determination of paritaprevir, ritonavir and ombitasvir in pharmaceutical dosage forms","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2019.e01518","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e01518"}}